| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778379 | European Urology | 2018 | 4 Pages |
Abstract
Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancer patients has been linked to resistance to abiraterone and enzalutamide. We designed a blood test to detect AR-Vs that can be performed more routinely than tests involving circulating tumour cells and found that patients with AR-Vs still benefit from these effective treatments.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Sarah Q. To, Edmond M. Kwan, Heidi C. Fettke, Andrew Mant, Maria M. Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenhöfer, Arun A. Azad,